Prothena | PRTA - Interest Expense On Debt

Stock Price
10.75
Daily Change
0.02 0.19%
Monthly
15.47%
Yearly
10.82%
Q2 Forecast
10.43

Prothena reported $2.62M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
Akebia Therapeutics 4.83M 359.32M Dec/2025
ALKERMES USD 12.28M 7.63M Dec/2025
Alnylam Pharmaceuticals USD 129.34M 84.94M Dec/2025
Amgen USD 653M 32M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.78M 199K Dec/2025
Exelixis USD 23.4M 3.9M Sep/2023
Immunic 400K 400K Dec/2024
Incyte USD 582K 10K Dec/2025
Ionis Pharmaceuticals USD 18M 0 Dec/2025
MacroGenics USD 3.34M 2.54M Sep/2025
Nektar Therapeutics USD 9.77M 3.75M Dec/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Prothena USD 2.62M 350M Dec/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Ultragenyx Pharmaceutical USD 19M 4.85M Dec/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025
Xoma USD 3.4M 150K Jun/2024